Comparative Analysis of Chemotherapy and Immunotherapy in Treating Advanced Cancer
DOI:
https://doi.org/10.56294/hl2025855Keywords:
Chemotherapy, Immunotherapy, Advanced Cancer, Efficacy, Patient OutcomesAbstract
Cancer is still one of the main reasons of death in the world, and treating cancers in their later stages is very hard. Chemotherapy and immunotherapy are the two main ways to treat advanced cancer. They work in different ways and have different benefits and drawbacks. This essay looks at chemotherapy and immunotherapy side by side, comparing how well they work, how safe they are, and how they affect patient results when treating advanced cancers. Chemotherapy is a common treatment that targets cancer cells that divide quickly. This shrinks the growth and stops the disease from getting worse. While chemotherapy has been shown to help some types of cancer, it often comes with serious side effects like weakened immune systems, stomach problems, and hair loss that can make patients' quality of life very bad. Immunotherapy, on the other hand, uses the immune system to find cancer cells and kill them. Immunotherapy, on the other hand, can cause long-lasting recovery by activating immune reactions that target cancer cells, and in some cases, it has fewer side effects. Several methods are used in this method, including immune checkpoint inhibitors, monoclonal antibodies, and cancer medicines. Immunotherapy has shown promise in treating cancers that didn't respond to treatment before, like melanoma, lung cancer, and some types of lymphoma. On the other hand, immunotherapy can cause immune-related side effects like swelling in good organs, which could lead to major problems. This review looks at the most important studies and clinical trials that have compared how well and safely chemotherapy and immunotherapy treat advanced cancer. We look at the rates of reaction, total survival, progression-free survival, and unfavorable events that happen with these different types of treatment. The study also talks about the things that affect the choice of treatment, such as the type of cancer, the patient's health, and their previous treatment history.
References
[1] Doki, Y.; Ajani, J.A.; Kato, K.; Xu, J.; Wyrwicz, L.; Motoyama, S.; Ogata, T.; Kawakami, H.; Hsu, C.H.; Adenis, A.; et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 2022, 386, 449–462.
[2] Puhr, H.C.; Prager, G.W.; Ilhan-Mutlu, A. How we treat esophageal squamous cell carcinoma. ESMO Open 2023, 8, 100789.
[3] Sun, J.M.; Shen, L.; Shah, M.A.; Enzinger, P.; Adenis, A.; Doi, T.; Kojima, T.; Metges, J.P.; Li, Z.; Kim, S.B.; et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet 2021, 398, 759–771.
[4] Obermannová, R.; Alsina, M.; Cervantes, A.; Leong, T.; Lordick, F.; Nilsson, M.; van Grieken, N.C.T.; Vogel, A.; Smyth, E.C. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2022, 33, 992–1004.
[5] Xu, J.; Lu, D.; Zhang, L.; Li, J.; Sun, G. Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer. Cancer Med. 2019, 8, 7253–7264.
[6] Li, T.; Lv, J.; Li, F.; Diao, P.; Wang, J.; Li, C.; Liang, L.; Sun, L. Prospective Randomized Phase 2 Study of Concurrent Chemoradiation Therapy (CCRT) Versus Chemotherapy Alone in Stage IV Esophageal Squamous Cell Carcinoma (ESCC). Int. J. Radiat. Oncol. Biol. Phys. 2016, 96, S1.
[7] Chen, Y.; Cheng, X.; Song, H.; Wu, A.J.; Ku, G.Y.; Lee, P.; Slingerland, M.; Koyanagi, K.; Ke, S.; Qiu, H.; et al. Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J. Thorac. Dis. 2019, 11, 1536–1545.
[8] Moreno, A.C.; Zhang, N.; Giordano, S.; Komaki, R.U.; Liao, Z.; Nguyen, Q.N.; Hofstetter, W.; Murphy, M.B.; Lin, S.H. Comparative Effectiveness of Chemotherapy Alone Versus Chemotherapy and Radiation Therapy for Patients with Stage IV Esophageal Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2017, 99, E172–E173.
[9] Wada, Y.; Anbai, A.; Takagi, N.; Kumagai, S.; Okuyama, E.; Nanjo, H.; Sato, Y.; Motoyama, S.; Hashimoto, M. Outcomes of Definitive Chemoradiotherapy for Stage IVa (T4b vs. N4) Esophageal Squamous Cell Carcinoma Based on the Japanese Classification System: A Retrospective Single-Center Study. Cancers 2020, 13, 8.
[10] Ishida, K. Phase II Study of Cisplatin and 5-Fluorouracil with Concurrent Radiotherapy in Advanced Squamous Cell Carcinoma of the Esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Japan J. Clin. Oncol. 2004, 34, 615–619.
[11] Chen, B.; Deng, M.; Yang, C.; Dragomir, M.P.; Zhao, L.; Bai, K.; Xi, M.; Hu, Y.; Zhu, Y.; Li, Q. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis. Radiother. Oncol. 2021, 158, 191–199.
[12] Makino, T.; Yamasaki, M.; Tanaka, K.; Miyazaki, Y.; Takahashi, T.; Kurokawa, Y.; Motoori, M.; Kimura, Y.; Nakajima, K.; Mori, M.; et al. Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review. Ann. Gastroent Surg. 2019, 3, 169–180.
[13] Zhu, S.; Zhang, T.; Zheng, L.; Liu, H.; Song, W.; Liu, D.; Li, Z.; Pan, C.X. Combination strategies to maximize the benefits of cancer immunotherapy. J. Hematol. Oncol. 2021, 14, 156.
[14] Liu, P.; Chen, J.; Zhao, L.; Hollebecque, A.; Kepp, O.; Zitvogel, L.; Kroemer, G. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. Oncoimmunology 2022, 11, 2093518.
[15] Kroemer, G.; Galassi, C.; Zitvogel, L.; Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 2022, 23, 487–500.
[16] Zitvogel, L.; Pitt, J.M.; Daillere, R.; Smyth, M.J.; Kroemer, G. Mouse models in oncoimmunology. Nat. Rev. Cancer 2016, 16, 759–773.
[17] Ma, Y.; Adjemian, S.; Mattarollo, S.R.; Yamazaki, T.; Aymeric, L.; Yang, H.; Portela Catani, J.P.; Hannani, D.; Duret, H.; Steegh, K.; et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013, 38, 729–741.
[18] Limagne, E.; Thibaudin, M.; Nuttin, L.; Spill, A.; Derangere, V.; Fumet, J.D.; Amellal, N.; Peranzoni, E.; Cattan, V.; Ghiringhelli, F. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol. Res. 2019, 7, 1958–1969.
[19] Li, Y.; Zhang, H.; Li, Q.; Zou, P.; Huang, X.; Wu, C.; Tan, L. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Lett. 2020, 495, 12–21.
[20] Fukushima, H.; Yoshida, S.; Kijima, T.; Nakamura, Y.; Fukuda, S.; Uehara, S.; Yasuda, Y.; Tanaka, H.; Yokoyama, M.; Matsuoka, Y.; et al. Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti-PD-1 Treatment Efficacy in Urothelial Carcinoma. Int. J. Mol. Sci. 2021, 22, 535.
[21] Shan, C.K.; Du, Y.B.; Zhai, X.T.; Wang, Y.X.; Li, Y.; Gong, J.H.; Ge, Z.J.; Liu, X.J.; Zhen, Y.S. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8(+) T cell augmentation. Cancer Chemother. Pharmacol. 2021, 87, 425–436.
[22] Yamazaki, T.; Buque, A.; Ames, T.D.; Galluzzi, L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology 2020, 9, 1721810.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pragati Aniket Manoli, Rashmi Gudur, Jatin Khurana, Aakash Sharma, Pramod Reddy, Soumya Surath Panda (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
